This included innovative medicines such as sofosbuvir whose planned market entry hit public payers of high-income countries unprepared. The 2015 Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference presented major challenges in achieving equitable access to affordable medicines not just in low- and middle-income countries but in high-income countries as well. 1WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria 2University of Huddersfield, Huddersfield, United Kingdom 3Department of Health Care Management, Technische Universität Berlin, Berlin, Germany 4Andalusian School of Public Health (EASP), Granada, Spain 5WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, the Netherlands 6WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal (Westville Campus), Durban, KwaZulu-Natal 4000, South Africa 7WHO Collaborating Centre in Pharmaceutical Policy, Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |